IOZK analysis proves good tolerability of IOZK immunotherapy in diffuse intrinsic pontine glioma (DIPG)
Together with an international group of scientists from Germany, Switzerland and the USA, the IOZK team publishes a retrospective analysis of the use of IOZK immunotherapy in diffuse intrinsic pontine glioma (DIPG). It demonstrates the good tolerability and potential clinical benefit of the combination of vaccination with dendritic cells, oncolytic virotherapy with the Newcastle disease virus and modulated electrohyperthermia.
